Navigation Links
AMRI Announces Strategic Contract with Knopp Biosciences
Date:9/17/2012

ALBANY, N.Y., Sept. 17, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has entered into a new strategic agreement with Knopp Biosciences LLC, a drug discovery and development company focused on breakthrough treatments for unmet needs in neurological disorders.  

(Logo:  http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Under the two-year term of the FTE agreement, AMRI will provide various discovery-related services that include medicinal chemistry, DMPK and computer-aided drug discovery (CADD). As part of the scope of work, AMRI scientists will collaborate with Knopp scientists and project leaders on selected novel drug discovery programs. The collaboration is extendable after two years by mutual agreement.

"We are pleased to expand our relationship with Knopp Biosciences, a company that values innovation through collaboration," said AMRI's Chairman, President and CEO, Thomas E. D'Ambra, Ph.D. "This agreement will combine AMRI's broad range of drug discovery capabilities, with more than 20 years of CNS experience, to assist Knopp in its goal of delivering safe and effective treatments for unmet medical need."

This agreement builds on and strengthens the strategic business relationship that already exists between Knopp Biosciences and AMRI. Since 2006, AMRI has worked with Knopp to provide early process development work, route development, and small-scale and large-scale cGMP manufacturing, as well as analytical method development and validation support.

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success, and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For press releases and additional information about the company, please visit www.amriglobal.com.

About Knopp Biosciences LLC
Knopp Biosciences LLC, based in Pittsburgh, PA, USA, is a drug discovery and development company focused on delivering breakthrough treatments for unmet needs in neurology through innovation, experience, and partnership. The company's lead product candidate is dexpramipexole, an orally bioavailable small molecule in Phase 3 development for the treatment of ALS. Biogen Idec holds an exclusive worldwide license from Knopp to develop and commercialize dexpramipexole, with Knopp providing development support and conducting certain U.S. commercialization activities. Knopp's discovery platform is directed to identifying next generation mitochondrial bioenergetic modulators for the treatment of ALS, Parkinson's disease, and other neurodegenerative disorders, as well as ion channel modulators for the treatment of epilepsy. For additional information about the company, please visit www.knoppneurosciences.com.


'/>"/>
SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ceramic Society announces selection of Ichinose, Lawn and Moskowitz as 2012 Distinguish Life Members
2. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
3. Sequenom Announces Participation At Two Upcoming Investor Conferences
4. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
5. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
6. Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
7. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
8. Unprecedented Donation by Korean Stem Cell Leader: Dr. Jeong-Chan Ra of RNL Bio announces the donation of 90% of his wealth
9. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems Announces Successful Production of Hemp Harvesting for High Value CBD Oil
10. BIOCOM Announces Endorsement in 52nd Congressional District Race
11. The Acta Materialia Inc Announces New Chairman of the Board of Governors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):